share_log

Jo-Jo Capital Canada Ltd. Enters Into Letter of Intent to Complete Qualifying Transaction With 9302204 Canada Inc. (O/a Cheelcare)

Jo-Jo Capital Canada Ltd. Enters Into Letter of Intent to Complete Qualifying Transaction With 9302204 Canada Inc. (O/a Cheelcare)

Jo-Jo Capital Canada Ltd. 與 9302204 Canada Inc.(o/a Cheelcare)簽訂了完成合格交易的意向書
GlobeNewswire ·  01/25 08:00

NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY OF THE SECURITIES IN THE UNITED STATES. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER OR SALE OF SECURITIES IN THE UNITED STATES.

不用於向美國電報社分發或在美國傳播。本新聞稿不構成美國任何證券的賣出要約或收購要約的邀請。這些證券過去和將來都不會根據經修訂的1933年《美國證券法》進行註冊( “美國證券法”)或任何州證券法,除非根據《美國證券法》和適用的州證券法進行註冊或獲得此類註冊的豁免,否則不得在美國境內或向美國個人發行或出售。本新聞稿不構成在美國的證券要約或出售。

TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Jo-Jo Capital Canada Ltd. ("Jo-Jo") is pleased to announce that it has entered into a binding letter of intent dated January 24, 2024 (the "LOI") with 9302204 Canada Inc. (o/a Cheelcare) ("Cheelcare") pursuant to which Jo-Jo proposes to acquire all of the issued and outstanding securities of Cheelcare in exchange for the issuance of securities of Jo-Jo, which will result in Cheelcare becoming a wholly-owned subsidiary of Jo-Jo (the "Cheelcare Transaction"). The Cheelcare Transaction, assuming the completion of the Private Placement (as defined below), will result in a reverse take-over of Jo-Jo where the existing shareholders of Cheelcare will own a majority of the outstanding common shares of Jo-Jo (the "Jo-Jo Common Shares") and Jo-Jo is expected be renamed, subject to shareholder approval, to such name as Cheelcare may determine (the "Resulting Issuer"). Upon completion of the Cheelcare Transaction, it is anticipated that the Resulting Issuer will be a Technology Issuer.

多倫多,2024年1月24日(GLOBE NEWSWIRE)——加拿大Jo-Jo資本有限公司(“Jo-Jo”)欣然宣佈,它已於2024年1月24日與9302204 Canada Inc.(o/a Cheelcare)(“Cheelcare”)簽訂了具有約束力的意向書(“LOI”),根據該意向書,Jo-Jo提議收購Cheelcare的所有已發行和流通證券以換取Jo-Jo發行證券,這將使Cheelcare成爲Jo-Jo的全資子公司(“Cheelcare交易”)。假設私募股權配售已經完成(定義見下文),Cheelcare交易將導致對Jo-Jo的反向收購,Cheelcare的現有股東將擁有Jo-Jo的大部分已發行普通股(“Jo-Jo普通股”),經股東批准,預計Jo-Jo將重命名爲Cheelcare可能確定的名稱(“最終發行人”)。Cheelcare交易完成後,預計最終發行人將成爲技術發行人。

Trading in the Jo-Jo Common Shares will be halted in accordance with the policies of the TSX Venture Exchange (the "TSXV") and will remain halted until such time as all required documentation in connection with the Cheelcare Transaction has been filed with and accepted by the TSXV and permission to resume trading has been obtained from the TSXV.

根據多倫多證券交易所風險交易所(“多倫多證券交易所”)的政策,Jo-Jo普通股的交易將暫停,並將一直暫停,直到與Cheelcare交易有關的所有所需文件已提交併獲得多倫多證券交易所接受並獲得多倫多證券交易所恢復交易的許可。

The Qualifying Transaction

符合條件的交易

Jo-Jo is a capital pool company and intends that the Cheelcare Transaction will constitute its "Qualifying Transaction" under Policy 2.4 – Capital Pool Companies of the TSXV ("Policy 2.4"). The Cheelcare Transaction will not constitute a non-arm's length qualifying transaction or a related party transaction pursuant to the policies of the TSXV.

Jo-Jo是一家資本池公司,打算將Cheelcare交易構成其 “合格交易” 政策 2.4 — 資本池公司 多倫多證券交易所(“政策2.4”)。根據多倫多證券交易所的政策,Cheelcare交易不構成非正常交易或關聯方交易。

Pursuant to the terms and conditions of the LOI, Jo-Jo and Cheelcare will negotiate and enter into a definitive agreement (the "Definitive Agreement") incorporating the principal terms of the Cheelcare Transaction as described in the LOI and this press release. There is no assurance that a Definitive Agreement will be successfully negotiated or entered into. The terms and conditions outlined in the LOI are binding on the parties and the LOI is expected to be superseded by the Definitive Agreement to be negotiated between the parties. The Cheelcare Transaction will be structured as a share exchange, plan of arrangement, amalgamation or other form of business combination based on the advice of the parties' respective advisors and taking into account various securities, tax, operating and other considerations.

根據意向書的條款和條件,Jo-Jo和Cheelcare將談判並簽訂最終協議(“最終協議”),其中納入意向書和本新聞稿中描述的Cheelcare交易的主要條款。無法保證最終協議會成功談判或簽訂。意向書中概述的條款和條件對雙方具有約束力,預計意向書將被雙方談判的最終協議所取代。Cheelcare交易將根據雙方各自顧問的建議,並考慮到各種證券、稅收、運營和其他考慮因素,以股票交易所、安排計劃、合併或其他形式的業務合併爲結構。

As consideration for the acquisition of all of the outstanding securities of Cheelcare, holders of issued and outstanding common shares of Cheelcare ("Cheelcare Common Shares") will receive one (1) post-consolidation Jo-Jo Common Share for each one (1) post-Cheelcare Split Cheelcare Common Share.

作爲收購Cheelcare所有已發行證券的對價,Cheelcare已發行和流通普通股(“Cheelcare普通股”)的持有人將在合併後每股Cheelcare拆分Cheelcare普通股獲得一(1)股Jo-Jo普通股。

Immediately prior to the completion of the Cheelcare Transaction, it is anticipated that, Jo-Jo will consolidate its issued and outstanding Jo-Jo Common Shares on the basis of two (2) pre-consolidation Jo-Jo Common Shares for each one (1) post-consolidation Jo-Jo Common Share (the "Jo-Jo Consolidation Ratio") as a condition to the completion of the Cheelcare Transaction (the "Jo-Jo Consolidation"). Currently there are 8,198,750 Jo-Jo Common Shares issued and outstanding. All incentive stock options and outstanding warrants of Jo-Jo are anticipated to be adjusted on the basis of the Jo-Jo Capital Consolidation Ratio.

預計在Cheelcare交易完成之前,Jo-Jo將在合併後每股一(1)股合併後的Jo-Jo普通股(“Jo-Jo合併比率”)的兩(2)股合併前合併其已發行和流通的Jo-Jo普通股,合併其已發行和流通的Jo-Jo普通股,以此作爲Cheelcare交易(“Jo-Jo合併”)完成的條件。目前,共發行和流通了8,198,750股Jo-Jo普通股。Jo-Jo的所有激勵性股票期權和未償還認股權證預計將根據Jo-Jo資本整合比率進行調整。

In addition, immediately prior to the completion of the Cheelcare Transaction, Cheelcare will split its issued and outstanding Cheelcare Common Shares on such basis as shall result in Cheelcare having 34,000,000 Cheelcare Common Shares (the "Cheelcare Share Split Ratio") issued and outstanding following completion of the split, excluding any securities issued in the Private Placement (as defined below) and the Debenture Conversion (as defined below) as a condition to the completion of the Cheelcare Transaction (the "Cheelcare Split"). There are currently 8,005,690 Cheelcare Common Shares issued and outstanding. All incentive stock options of Cheelcare are anticipated to be adjusted on the basis of the Cheelcare Share Split Ratio.

此外,在Cheelcare交易完成之前,Cheelcare將分割其已發行和流通的Cheelcare普通股,這將使Cheelcare在拆分完成後發行和流通的34,000,000股Cheelcare普通股(“Cheelcare股票分割比率”),不包括以私募方式(定義見下文)和債券轉換(定義見下文)中發行的任何證券完成Cheelcare交易(“Cheelcare拆分”)的條件。目前已發行和流通的Cheelcare普通股爲8,005,690股。預計Cheelcare的所有激勵性股票期權都將根據Cheelcare的股票分割比率進行調整。

Cheelcare intends to conduct, and it is a condition of the Cheelcare Transaction for Cheelcare to close, a concurrent private placement (the "Private Placement") for minimum aggregate gross proceeds of C$2,500,000 through the offering of subscription receipts of Cheelcare to be sold at an issue price of C$0.25, the terms of which are currently being negotiated. Subject to the satisfaction of certain customary conditions, it is anticipated the subscription receipts shall automatically convert into Cheelcare Common Shares on a post-Cheelcare Split basis. Further disclosure of the terms and conditions of the Private Placement will be provided upon the successful negotiation and the terms and conditions thereof. There is no assurance that such negotiations will be concluded successfully. Cheelcare intends to use the net proceeds from the Private Placement for business development, working capital requirements and general corporate purposes.

Cheelcare打算同時進行私募配售(“私募配售”),通過發行Cheelcare的認購收據,以0.25加元的發行價出售,同時進行私募配售(“私募配售”),以0.25加元的發行價出售,其條款目前正在談判中。在滿足某些慣例條件的前提下,預計認購收據將在CheelCare拆分後的基礎上自動轉換爲Cheelcare普通股。在談判成功後,將進一步披露私募的條款和條件及其條款和條件。無法保證此類談判會成功結束。Cheelcare打算將私募的淨收益用於業務發展、營運資金要求和一般公司用途。

Significant Conditions to Closing

關閉的重要條件

The completion of the Cheelcare Transaction is subject to a number of conditions precedent, including but not limited to satisfactory due diligence review, negotiation and execution of the Definitive Agreement and accompanying transaction documents, approval by the boards of directors of each of Jo-Jo and Cheelcare, approval of the shareholders of each of Jo-Jo and Cheelcare (if required), obtaining necessary third party approvals, TSXV acceptance, closing of the Private Placement for gross proceeds of not less than C$2,500,000 and preparation and filing of a management information circular or filing statement outlining the definitive terms of the Cheelcare Transaction and describing the business to be conducted by the Resulting Issuer following completion of the Cheelcare Transaction, in accordance with the policies of the TSXV. There can be no assurance that the Cheelcare Transaction or the Private Placement will be completed as proposed, or at all. The obligations of Jo-Jo and Cheelcare pursuant to the LOI shall terminate in certain specified circumstances, including but not limited to in the event that a Definitive Agreement is not entered into between the parties by February 29, 2024.

Cheelcare交易的完成需要滿足一些先決條件,包括但不限於令人滿意的盡職調查審查、最終協議和隨附交易文件的談判和執行、Jo-Jo和Cheelcare各自董事會的批准、Jo-Jo和Cheelcare各股東的批准(如果需要)、獲得必要的第三方批准、TSXV的接受、總收益的私募結束不少於 2,500,000 加元,並準備和提交管理信息通告或申報聲明,概述了Cheelcare交易的最終條款,並描述了最終發行人在Cheelcare交易完成後將根據多倫多證券交易所的政策開展的業務。無法保證Cheelcare交易或私募會按提議完成,或者根本無法保證。Jo-Jo和Cheelcare根據意向書承擔的義務將在某些特定情況下終止,包括但不限於雙方在2024年2月29日之前未簽訂最終協議的情況。

Additionally, it is a condition of the Cheelcare Transaction for Cheelcare to convert $1,133,300 principal amount in unsecured convertible debentures outstanding into Cheelcare Shares at a conversion price which is at a 25% discount to the valuation ascribed to the Cheelcare Shares in the Cheelcare Transaction (the "Debenture Conversion").

此外,Cheelcare交易的條件是將本金1,133,300美元的已發行無抵押可轉換債券轉換爲Cheelcare股票,其轉換價格比Cheelcare交易(“債券轉換”)中Cheelcare股票的估值折扣25%。

This is an initial press release. Jo-Jo plans to issue a comprehensive press release in accordance with Policy 2.4 once it has entered into the Definitive Agreement to provide, among other things, selected information respecting Cheelcare, the Private Placement and the biographies of the anticipated directors and officers of the Resulting Issuer. Additional information with respect to Cheelcare and the Transaction will be included in the Company's management information circular or filing statement to be filed in connection with the Transaction, which will be available under Jo-Jo's SEDAR profile at .

這是最初的新聞稿。Jo-Jo計劃在簽訂最終協議後根據政策2.4發佈一份全面的新聞稿,除其他外,提供有關Cheelcare、私募以及最終發行人的預期董事和高級管理人員簡歷的精選信息。有關Cheelcare和本次交易的更多信息將包含在公司提交的與該交易相關的管理信息通告或申報聲明中,該通告或申報聲明將在Jo-Jo的SEDAR個人資料下提供,網址爲。

Sponsorship

贊助

Sponsorship of a Qualifying Transaction is required by the TSXV unless a waiver from the sponsorship requirement is obtained. Jo-Jo intends to apply for a waiver from sponsorship for the Cheelcare Transaction. There is no assurance that a waiver from this requirement will be obtained.

除非獲得贊助要求的豁免,否則多倫多證券交易所要求贊助合格交易。Jo-Jo打算爲Cheelcare交易申請贊助豁免。無法保證會獲得對這一要求的豁免。

About 9302204 Canada Inc. (o/a Cheelcare)

關於 9302204 加拿大公司(o/a Cheelcare)

9302204 Canada Inc. (o/a CheelcareTM) is a company incorporated under the Canada Business Corporations Act and stands as an innovative technological and manufacturing company dedicated to removing barriers to mobility. By harnessing the power of artificial intelligence and breakthrough engineering, Cheelcare is determined to radically improve the lives of millions living with disabilities by delivering next-generation, life-changing technology to the multi-billion wheelchair market. Innovations that are not just a step forward but a leap into uncharted territories that redefine possibilities. Cheelcare's alignment with government funding programs ensures that customers can access its critical products through resilient funding streams, even in diverse market conditions.

9302204 加拿大公司 (o/a Cheelcare)TM)是一家根據《加拿大商業公司法》註冊成立的公司,是一家致力於消除出行障礙的創新技術和製造公司。通過利用人工智能和突破性工程的力量,Cheelcare決心通過向數十億美元的輪椅市場提供改變生活的下一代技術,從根本上改善數百萬殘疾人的生活。創新不僅是向前邁出的一步,而且是向未知領域的飛躍,重新定義了可能性。Cheelcare與政府資助計劃保持一致,確保即使在不同的市場條件下,客戶也可以通過彈性資金流獲得其關鍵產品。

Cheelcare's portfolio includes three rapidly growing lines of patented devices: innovative safety accessories, the industry-award-winning power add-on for manual wheelchairs known as Companion, and Curio, a technologically advanced robotic complex rehab power wheelchair.

Cheelcare的產品組合包括三種快速增長的專利設備系列:創新的安全配件、業界獲獎的名爲Companion的手動輪椅電動附加組件,以及技術先進的複雜機器人康復電動輪椅Curio。

Curio sets new industry benchmarks with an unprecedented range of movement, omnidirectional tilting, and self-levelling capabilities – pioneering a new dimension in mobility.

Curio 憑藉前所未有的運動範圍、全向傾斜和自平衡能力設定了新的行業基準,開創了出行的新維度。

Cheelcare is redefining accessibility for millions. Its team of engineers and visionaries is on a mission to continuously expand its life-changing impact in the global market.

Cheelcare正在重新定義數百萬人的可訪問性。其工程師和遠見卓識團隊的使命是不斷擴大其在全球市場上改變生活的影響。

About Jo-Jo Capital Canada Ltd.

關於 Jo-Jo Capital Canada Ltd

Jo-Jo is a capital pool company created pursuant to the policies of the TSXV. It does not own any assets, other than cash or cash equivalents and its rights under the LOI. The principal business of Jo-Jo is to identify and evaluate opportunities for the acquisition of an interest in assets or businesses and, once identified and evaluated, to negotiate an acquisition or participation subject to acceptance by the TSXV so as to complete a Qualifying Transaction in accordance with Policy 2.4.

Jo-Jo是一家根據多倫多證券交易所的政策創建的資本池公司。除了現金或現金等價物及其在意向書下的權利外,它不擁有任何資產。Jo-Jo的主要業務是確定和評估收購資產或企業權益的機會,並在確定和評估後,就收購或參與進行談判,但須經多倫多證券交易所接受,以便根據政策2.4完成合格交易。

Forward-Looking Statements Disclaimer

前瞻性聲明免責聲明

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險投資交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Jo-Jo assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Jo-Jo. Additional information identifying risks and uncertainties is contained in filings by Jo-Jo with the Canadian securities regulators, which filings are available at .

本新聞稿中的某些信息可能包含前瞻性陳述。這些信息基於當前的預期,這些預期存在難以預測的重大風險和不確定性。實際結果可能與任何前瞻性陳述中建議的結果存在重大差異。除非適用於Jo-Jo的證券法有要求,否則Jo-Jo沒有義務更新前瞻性陳述,也沒有義務更新實際業績可能與前瞻性陳述中反映的結果不同的原因。識別風險和不確定性的其他信息包含在Jo-Jo向加拿大證券監管機構提交的文件中,這些文件可在以下網址查閱

Completion of the Cheelcare Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and, if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Cheelcare交易的完成取決於許多條件,包括但不限於多倫多證券交易所的接受,以及根據多倫多證券交易所的要求,還需要獲得大多數少數股東的批准。在適用的情況下,在獲得所需的股東批准之前,交易無法完成。無法保證交易會按提議完成或根本無法保證。

Investors are cautioned that, except as disclosed in the filing statement or management information circular to be prepared in connection with the Cheelcare Transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

提醒投資者,除非在與Cheelcare交易相關的申報聲明或管理信息通告中披露的內容,否則發佈或收到的有關該交易的任何信息可能不準確或不完整,不應作爲依據。資本池公司的證券交易應被視爲高度投機性。

The TSXV has in no way passed upon the merits of the proposed Cheelcare Transaction and has neither approved nor disapproved the contents of this press release.

多倫多證券交易所根本沒有透露擬議的Cheelcare交易的優點,也沒有批准或不批准本新聞稿的內容。

The Jo-Jo Common Shares will remain halted until such time as permission to resume trading has been obtained from the TSXV. Jo-Jo is a reporting issuer in Alberta, British Columbia, and Ontario.

在獲得多倫多證券交易所恢復交易的許可之前,Jo-Jo普通股將保持暫停狀態。Jo-Jo是艾伯塔省、不列顛哥倫比亞省和安大略省的申報發行人。

For more information about Jo-Jo, please contact Peter Schloo, Chief Executive Officer, at (905) 505-0918.

有關Jo-Jo的更多信息,請致電 (905) 505-0918與首席執行官彼得·施洛聯繫。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論